2022
DOI: 10.1016/j.jacbts.2021.09.012
|View full text |Cite
|
Sign up to set email alerts
|

A Glimpse Into the Future of Transcatheter Interventional Heart Failure Therapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 49 publications
0
2
0
Order By: Relevance
“…Simultaneously, the care of heart failure patients is increasingly overlapping with interventional cardiology and transcatheter interventional therapies. 7 Structural interventions are being used to address both acute and chronic heart failure in an aging and growing population of patients with advanced heart failure. As such, several major structural interventional cardiology trials such as COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), MITRA-FR (Percutaneous Repair With the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), and PARTNER 3 (Placement of Aortic Transcatheter Valves 3) have incorporated rehospitalizations end points into their primary composite outcomes.…”
Section: Readmissions In Structural Heart Disease Trialsmentioning
confidence: 99%
“…Simultaneously, the care of heart failure patients is increasingly overlapping with interventional cardiology and transcatheter interventional therapies. 7 Structural interventions are being used to address both acute and chronic heart failure in an aging and growing population of patients with advanced heart failure. As such, several major structural interventional cardiology trials such as COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), MITRA-FR (Percutaneous Repair With the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation), and PARTNER 3 (Placement of Aortic Transcatheter Valves 3) have incorporated rehospitalizations end points into their primary composite outcomes.…”
Section: Readmissions In Structural Heart Disease Trialsmentioning
confidence: 99%
“…Moreover, catheter-based approaches to improve renal arterial inflow or reduce renal venous congestion are under clinical investigation and may impart benefit by improving renal perfusion. 6 The present work 2 highlights yet another therapeutic strategy for renal dysfunction after MI—targeting cardiac afferents.…”
mentioning
confidence: 91%